Novartis runs an annual program to support independent eye care initiatives worldwide via grant funding, including some in the world’s most remote areas and deprived communities.
Talk to any cancer researcher or doctor today and what you hear is wonder and hope.
Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.
Novartis is investing in thermal energy storage to minimize fuel costs and reduce the carbon footprint of new buildings.
Martin Edlund is a founding member and CEO of Malaria No More. During his tenure, he has implemented high-profile engagement campaigns leveraging cutting edge mobile, social, and e-commerce platforms. Prior to Malaria No More, Martin was a journalist and political consultant.
Engineers spent two decades developing a new generation of contact lenses, Dailies Total1, to address the issue of discomfort users experience with existing silicone hydrogel lenses.
The majority of Europeans can’t identify the warning signs of heart failure, a life threatening disease, which affects one in five people in the region.
Novartis researchers use automation to rapidly identify starting points for new drugs.
Ahead of World Malaria Day, Novartis and Malaria No More delivered 2 million pediatric antimalarials to Zambia provided through the Power of One campaign.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.